Cargando…
HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
Clinical progress in the field of HER2-positive breast cancer therapy has been dramatically improved by understanding of the immune regulatory mechanisms of tumor microenvironment. Passive immunotherapy utilizing recombinant monoclonal antibodies (mAbs), particularly trastuzumab and pertuzumab has p...
Autores principales: | Arab, Atefeh, Yazdian-Robati, Rezvan, Behravan, Javad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223380/ https://www.ncbi.nlm.nih.gov/pubmed/31915932 http://dx.doi.org/10.1007/s00005-019-00566-1 |
Ejemplares similares
-
Comparative proteomics study of proteins involved in induction of higher rates of cell death in mitoxantrone-resistant breast cancer cells MCF-7/MX exposed to TNF-α
por: Norouzi, Saeed, et al.
Publicado: (2020) -
Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model
por: Razazan, Atefeh, et al.
Publicado: (2017) -
Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice
por: Razazan, Atefeh, et al.
Publicado: (2019) -
Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023) -
Immunotherapies against HER2-Positive Breast Cancer
por: Duro-Sánchez, Santiago, et al.
Publicado: (2023)